The relationship between congenital infections and autism spectrum disorder: a systematic review. - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/42501972
Explore potential connections between congenital infections and ASD. The study suggests varying associations depending on the pathogen, with heterogeneous data and NOS score variability.
The review found no consistent causal link between congenital infections and ASD; data were heterogeneous with varying NOS scores, though some infections showed possible correlations.
Adapting mHealth Interventions to Improve Self-Management of HIV and Reduce Substance Use Among Emerging Adults in Zambia: Protocol for a Randomized Controlled Trial. - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/42470201
Explore a multicomponent mobile health intervention for HIV self-management and substance use reduction among young Zambians, using the MOST framework for efficacy assessment.
The study develops a multicomponent mHealth intervention for young Zambians with HIV, adapting Healthy Choices for mobile delivery and adding motivational texts, using the MOST framework.
Month 12 outcomes of switching to long-acting cabotegravir + rilpivirine with an oral lead-in versus continuing bictegravir/emtricitabine/tenofovir alafenamide in the Phase 3b randomized SOLAR study - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/41110828/
Cabotegravir + rilpivirine (CAB + RPV) dosed every 2 months (Q2M) is the only complete long-acting (LA) regimen for maintaining HIV-1 virologic suppression. In some regions, prescribing information mandates a...
Phase 3b SOLAR study showed switching virologically suppressed adults to long-acting cabotegravir plus rilpivirine with an oral lead-in maintained comparable viral suppression, was well tolerated, and was preferred by most participants.
Genotyping not required for sustained effectiveness of long-acting cabotegravir plus rilpivirine: evidence from the RELATIVITY cohort - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/41183264/
In this large real-world cohort, the absence of genotypic data did not affect LAI CAB+RPV effectiveness in virologically suppressed PWH. Limitations, including ambispective design, short follow-up, and low non-B subtype...
Real-world cohort data suggest long-acting cabotegravir plus rilpivirine maintains high virologic suppression in HIV regardless of pre-switch genotyping, supporting sustained effectiveness without routine genotype testing in virologically suppressed patients.